Welcome to This Week in Infectious Disease. This week we're covering 10 notable papers spanning major clinical trials in bacterial infections, new data on vaccine effectiveness for COVID-19 and Mpox, and a look at the future of antimicrobial discovery and global disease surveillance. Let's dive in.

This week's papers:

1. An HIV vaccine blueprint. — Science (New York, N.Y.) 2026
2. Neutralising antibody responses to MPXV clades Ia, Ib, and IIb after infection or vaccination: a multicountry observational study. — The Lancet. Infectious diseases 2026
3. Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacterales: A Multicenter, Open-Label, Randomized Controlled Trial. — Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026
4. Deep learning-enabled discovery of antibiotics effective against Neisseria gonorrhoeae. — Science translational medicine 2026
5. Engineered antibodies bypass bacterial immune evasion to drive complement-mediated protection against lethal infections. — Science translational medicine 2026
6. Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults. — JAMA internal medicine 2026
7. Analysis of 173,303 exomes and genomes in the Pakistan Genome Resource. — Nature 2026
8. WHO estimates of the global, regional, and national burden of 14 foodborne diarrhoeal enteric hazards, 2000-21: an updated data synthesis. — The Lancet. Global health 2026
9. Identification of host gene transcripts by machine learning and their application to predict outcome in Ebola virus disease. — The Journal of infectious diseases 2026

Listen at AudioScholar